GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Pertuzumab (Perjeta), IV injection

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Perjeta - labeled renal guidance

Product / population
Pertuzumab (Perjeta), IV injection
Renal method
Creatinine clearance (CrCl), mL/min
Source revision
DailyMed SPL version 27, posted May 04, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Perjeta - product and source limitations

Verify that the order is for the intravenous pertuzumab product.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Perjeta - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Pertuzumab (Perjeta), IV injection

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 27, posted May 04, 2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

Use the usual pertuzumab dose at CrCl 30-90 mL/min. Data are inadequate to recommend a regimen below 30 mL/min. Verify that the order is for the intravenous pertuzumab product.

RDM74-perjeta-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f85d17-ab71-4f5b-9fe3-0b8c822f69ff
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 27, posted May 04, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
2eae016d6b055de43a5ff022fdd7bd52da01e052899dcbe9e56d5670f8df05b8

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-perjeta&s1=RDM74-perjeta-official&h1=9898d643de52611e9beffe611106260e391f19a5ce7eceb08b1d933addaea0f6

Top